Nutrien (NTR) was up 3% on a Q3 beat but the results weren’t the story, with management running a process on its phosphate business. Given the segment is only ~6% of NTR’s top line…

… and has been historically lumpy, a sale would reduce margin volatility

… and follow a series of streamlining initiatives including the wind down of its nitrogen ops in Trinidad and $600M Profertil sale. If a deal lines up with the 6-7x multiple NTR currently trades at…

it would put another ~$2.5B in Nutrien’s pocket - let’s see.

Disclaimer: Content on this site, including research reports, is provided by Bullpen Finance Inc. for informational purposes only and does not constitute investment advice. Bullpen Finance Inc. receives compensation from issuers for research coverage; such compensation does not influence opinions expressed. For complete disclosures, please see our Legal & Disclosures section.